Potential prophylactic role of aminoguanidine in diabetic retinopathy and nephropathy in experimental animals

Open access

Potential prophylactic role of aminoguanidine in diabetic retinopathy and nephropathy in experimental animals

This study sought to determine the potential prophylactic and antioxidant effects of aminoguanidine in experimentally induced diabetes. Four groups of Wistar rats, each composed of ten rats, were used. Two groups served as control. In group 3, diabetes was induced by a single intraperitoneal injection of streptozotocin (65 mg kg-1). In group 4, diabetes was induced and treated with aminoguanidine (100 mg kg-1 daily) orally for 3 months. Levels of serum glucose, glutathione peroxidase, glutathione reductase and erythrocytes catalase were analyzed on day 90 of the experiment. Retinal and kidney specimens were examined histopathologically after sacrifice of the animals. A significant antioxidant effect of aminoguanidine and its prophylactic role in diabetic retinopathy and nephropathy were observed in experimental animals.

A. W. Stitt, Advanced glycation: an important pathological event in diabetic and age related ocular disease, Br. J. Opthalmol. 25 (2001) 746-753; DOI: 10.1136/bjo.85.6.746.

A. W. Stitt, T. Bahduri, C. B. McMullen, T. A. Gardinger and D. B. Archer, Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats, Mol. Cell. Biol. Res. Commun. 3 (2000) 380-88; DOI: 10.1006/mcbr.2000.0243.

J. M. Hughes, E. G. Kuiper, I. Klaassen, P. Canning, A. W. Stitt and J. Vanbezo, Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina, Diabetologia 50 (2007) 1089-1098; DOI: 10.1007/s00125-007-0621-4.

H. Noh, K. H. Choi, D. S. Han and H. Y. Lee, High glucose increases inducible NO production in cultured rat mesengial cells. Possible role in fibronectin production, Nephron. 90 (2002) 78-85.

S. S. Ahanchi, V. N. Varu, N. D. Tsihlis, J. Martinez, C. G. Pearce, M. R. Kapadia, Q. Jiang, J. E. Saavedra, L. K. Keefer, J. A. Hrabie and M. R. Kibbe, Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome, Am. J. Physiol. Heart. Circ. Physiol. 295 (2008) 2388-2398.

G. P. Bautista, L. G. Sanchez, C. U. Cristobal, E. Tapia, V. Soto and C. M. Avila, Chronic inhibition of NOS-2 ameliorates renal injury, as well as COX-2 and TGF-beta 1 over expression in 5/6 neprhectomized rats, Nephrol. Diab. Transpl. 21 (2006) 3074-3081.

H. J. Han, J. L. Lee, S. H. Park, J. H. Lee and M. Taub, High glucose induced oxidative stress inhibits Na/glucose transporter activity in renal proximal tubule cells, Am. J. Physiol. Renal Physiol. 288 (2004) F988-F998; DOI: 10.1152/ajprenal.00327.2004.

M. C. Thomas, H. U. Forbes and M. E. Cooper, Advanced glycation end products and diabetic nephropathy, Am. J. Ther. 12 (2005) S62-S72; DOI: 10.1097/01.mjt.0000178769.52610.69.

S. Varsan, P. Foiles and H. Founds, Therapeutic potential of breakers of advanced glycation end product-protein cross links, Arch. Biochem. Biophys. 419 (2003) 89-96.

V. Brodiak and N. O. Sybirua, Effect of aminoguanidine on oxidative modification of proteins in experimental diabetes mellitus in rats, Ukr. Biochim. Zh. 78 (2006) 114-119.

O. Azal, A. Yohem, B. Cakir, A. Baydar, A. Corakei and M. Kutli, Effects of aminoguanidine and tolrestat on the development of ocular and renal structural changes in experimental diabetic rats, Diabetes Obes. Metab. 4 (2002) 75-79; DOI: 10.1046/j.1463-1326.2002.00182.x.

G. R. Stoppa, M. Cesquini, E. A. Roma, S. H. Ogo and M. A. Torsoni, Aminoguanidine prevented impairment of blood antioxidant system in insulin dependent diabetic rats, Life Sci. 78 (2006) 1352-1361; DOI: 10.1016/j.lfs.2005.07.031.

L. Zheng, B. Gong, D. A. Hatala and T. S. Kern, Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes, Invest. Ophth. Vis. Sci. 48 (2007) 361-367; DOI: 10.1167/iovs.06-0510.

D. J. Kelly, R. E. Gilbert, A. J. Cox, T. Soulis, G. Jerums and M. E. Cooper, Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy, J. Am. Soc. Nephrol. 12 (2001) 2098-2107.

H. Sugimoto, G. Grahovac, M. Zeisberg and R. Kalluri, Renal fibrosis and glumerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors, Diabetes 56 (2007) 1825-1833.

O. Adbelzaher, M. M. Adbelrahman, M. M. Hafez and F. M. Omran, Role of nitric oxide and reduced glutathione in the protective effects of aminoguanidine, gadolinium chloride and oleanolic acid against acetaminophen-induced hepatic and renal damage, Toxicology 234 (2007) 124-134.

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information

IMPACT FACTOR 2017: 1.071
5-year IMPACT FACTOR: 1.623

CiteScore 2017: 1.46

SCImago Journal Rank (SJR) 2017: 0.362
Source Normalized Impact per Paper (SNIP) 2017: 0.642

Cited By


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 109 109 12
PDF Downloads 22 22 2